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Promoting long-term adherence to lifestyle modiﬁcation and choice of antidiabetic agent with low hypoglycemia risk proﬁle and
positive weight proﬁle could be the most eﬀective strategy in achieving sustained glycemic control and in reducing comorbidities.
From this perspective, vast interest has been generated by glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl
peptidase-4 inhibitors (DPP-4i). In this review our ten-year clinical and laboratory experience by in vitro and in vivo studies
is reported. Herein, we reviewed available data on the eﬃcacy and safety proﬁle of GLP-1 receptor agonists and DPP-4i. The
introduction of incretin hormone-based therapies represents a novel therapeutic strategy, because these drugs not only improve
glycemia with minimal risk of hypoglycemia but also have other extraglycemic beneﬁcial eﬀects. In clinical studies, both GLP-1
receptor agonists and DPP-4i, improve β cell function indexes. All these agents showed trophic eﬀects on beta-cell mass in animal
studies. The use of these drugs is associated with positive or neucral eﬀect on body weight and improvements in blood pressure,
diabetic dyslipidemia, hepatic steazosis markets, and myocardialfunction. These eﬀects have the potential to reduce the burden of
cardiovascular disease, which is a major cause of mortality in patients with diabetes.
1.Introduction
The global prevalence of type 2 diabetic (T2DM) patients
estimated at 6.4% is expected to be close to 8% by 2030
[1]. The overall total predicted increase is thought to be due
largely to rising rates of overweight, obesity, physical inactiv-
ity, and population aging [2]. Improving glycaemic control
remains the most eﬀective therapeutic approach to reduce
the risk of development and/or progression of microvascu-
lar complications. Furthermore, a recent meta-analysis of
long-term, prospective randomized controlled clinical trials
(UKPDS, PROactive, ADVANCE, VADT, and ACCORD)
revealed a signiﬁcant association between intensive blood
glucose control and incident cardiovascular events: a 0.9%
HbA1cdecreasewasrelatedtoareductionof17%innonfatal
MI (odds ratio (OR): 0.83, 95% conﬁdence interval (CI):
0.75–0.93) and 15% in coronary heart disease (OR: 0.85,
95% CI: 0.77–0.93) versus conventional therapy [3]. In a
metaregression analysis, higher body mass index (BMI),
duration of diabetes, and incidence of severe hypoglycaemia
were associated with greater risk of cardiovascular death
in intensive treatment groups [4]. Altogether, these results
underlinetheimportanceofachievingandmaintaining good
glycemic control, from the time of diagnosis, predominantly
through a tailored approach. Promoting long-term adher-
ence to lifestyle modiﬁcation and choice of antidiabetic
agent with low hypoglycemia risk proﬁle and positive weight
proﬁle could be the most eﬀective strategy in achieving
sustained glycemic control and in reducing comorbidities.
From this perspective, vast interest has been generated
by glucagon-like peptide-1 (GLP-1) receptor agonists and
dipeptidyl peptidase-4 inhibitors (DPP-4i) based on many
clinical studies revealing long-term glucose-lowering eﬃcacy
related to low hypoglycemic rates, positive/neutral weight
eﬀects, and amelioration of β cell function [5–7].
2.Background: ATen-YearClinicaland
LaboratoryExperience
GLP-1 is a gastrointestinal hormone, mainly secreted in
a nutrient-dependent manner, which enhances glucose-
induced insulin secretion and induces satiety. It has been2 Experimental Diabetes Research
reported that GLP-1 levels after an oral glucose load are
reduced in patients with T2DM [8] even if more recent data
suggest a controversial point of view [9]. The reduction of
oralglucose-stimulatedactiveGLP-1levelsinT2DMpatients
has also been observed during euglycaemic hyperinsuline-
mic clamp. This impairment, which is not the result of
diﬀerences in glycaemia or insulinaemia during assessment,
could contribute to the pathogenesis of hyperglycaemia
in T2DM [8] and in particular to the reduction of early
postprandial insulin secretion; in fact, the administration of
GLP-1 receptor antagonists to healthy volunteers elicits both
an impairment of meal-induced insulin secretion and an
increaseofpostprandialglycaemiasimilar tothatobservedin
T2DM. GLP-1 is rapidly inactivated by dipeptidyl peptidase-
4 (DPP-4), an enzyme produced by endothelial cells in dif-
ferent districts and that circulates in plasma. The reduction
of meal or oral-glucose-stimulated GLP-1 levels in T2DM
patients is probably due to both an impairment of secretion
and an increased degradation. The major limitation of using
native GLP-1 to treat diabetic patients is the short half-
life. There are now several compounds in various stages
of preclinical or clinical development for the treatment
of T2DM that utilize the GLP-1 signaling pathway; these
includeGLP-1 receptoragonists with extended half-lives and
DPP-4i that increase circulating levels of endogenous, intact,
and bioactive GLP-1 [10].
Metformin, ﬁrst drug of choice in the treatment of
T2DM,inducedasigniﬁcantincreaseofGLP-1(7–36)amide/
(7–37) at 30 and 60min after the oral glucose load in obese
nondiabetic subjects. In pooled human plasma, metformin
(0.1–0.5microg/mL) signiﬁcantly inhibited degradation of
GLP-1(7–36) amide after a 30min incubation at 37◦C;
similar results were obtained in a buﬀer solution containing
DPP-4. This eﬀect could be due to an inhibition of GLP-
1d e g r a d a t i o n[ 11]. This eﬀect was also present in obese
drug-na¨ ıve T2DM patients. In fact 4 weeks after treatment
with metformin 850mg three times daily, post-load GLP-
1 levels was signiﬁcantly increased [12]. Furthermore the
relationship between meal-induced GLP-1 secretion and
postprandial hyperglycemia was studied in 21 drug-na¨ ıve
T2DM patients. Blood glucose and active GLP-1 levels were
measured 0, 30, 60, 90, and 120min after a standard meal
test, and a continuous glucose monitoring (CGM) system
wasappliedforthefollowing3days.Asigniﬁcantinversecor-
relation between GLP-1 response and postprandial glucose
levels was observed for each additional unit of total energy
orcarbohydrate intake. A lower GLP-1 response is associated
with higher levels of HbA1c and with a greater degree of
meal-induced hyperglycemia, both during a meal test and
“real-life” condition [13].
GLP-1 and DPP-4 activity levels have been subsequently
studied during an oral glucose tolerance test (OGTT), in
order to investigate their modiﬁcation in patients with
diﬀerent glucose tolerance degree. At 30min GLP-1 level-
swere signiﬁcantly lower in subjects with impaired glucose
toleranceand T2DMcomparedtothose withnormal glucose
tolerance. The area under the curve of GLP-1 levels during
OGTT was signiﬁcantly diﬀerent among the three groups
with a signiﬁcant decrease between subjects with normal
and impaired glucose tolerance and between those with
normal glucose tolerance and type 2 diabetes mellitus. DPP-
4s h o w e dn os i g n i ﬁ c a n td i ﬀerence between the groups.
Therefore, an increase of GLP-1 degradation seems to be
not involved in the early stages of diabetes [14]. However,
chronic hyperglycaemia was signiﬁcantly associated to an
increased DPP-4 activity and mRNA expression in human
glomerular endothelial cells in vitro [15]. In order to assess
eﬀects of chronic hyperglycaemia on circulating DPP-IV
activity in vivo, we have analyzed diabetic patients not
adequately controlled. T2DM subjects with HbA1c levels
>8.5% showed signiﬁcantly higher DPP-4 activity than
patients aﬀected by newly diagnosed diabetes and Impaired
Glucose Tolerance (IGT). Variations in DPP-4 activity over
3 months in T2DM showed a signiﬁcant positive correla-
tion with HbA1C levels. Therefore, chronic hyperglycaemia
induced a signiﬁcant increase in DPP-4 activity in type
2 diabetic patients with poor metabolic control, probably
contributing to the reduction in circulating active GLP-
1 and subsequently to postprandial hyperglycaemia [16].
Moreover, the eﬀects of insulin sensitizers drugs, such as
Metformin and Rosiglitazone, on the modulation of GLP-
1 circulating levels, DPP-4 activity, and mRNA expression
wasevaluatedinhumanaorticendothelialcells(HAECs)and
human microvascular dermal endothelial cells (HMVECs)
exposed to high glucose concentration. Hyperglycemia is
associated to a signiﬁcant DPP-4 activity increase only
in microvascular endothelial cells. Rosiglitazone is able to
modulate in a negative manner the expression of DPP-4 but
not its activity in macrovascular endothelial cells, while at
2 4 ho fe x p o s u r ei ti sa b l et oi n c r e a s es i g n i ﬁ c a n t l yD P P - 4
activity but not its expression in microvascular endothelial
cells. Metformin at 48h in microvascular endothelial cells is
able to reduce in a signiﬁcant manner the activity of DPP-
4 but not its expression [17]. Therefore, the modulation of
D P P - 4s e e m st ob es i t es p e c i ﬁ c .
3.RationaleandExtraglycaemicEffectsof
Incretin Therapy
GLP-1 receptor agonists that resist degradation by DPP-4
and have protracted-action kinetics have been developed,
and DPP-4i that slow the enzymatic cleavage of native
GLP-1 provide alternative approaches to enhancing incretin-
mediated glucose control.
However, GLP-1 receptor agonists and DPP-4i are
premised on highly divergent mechanisms of action. DPP-
4 is ubiquitously expressed in many tissues and is involved
in a wide range of processes in addition to its inﬂuence on
incretin hormone biological eﬀects. GLP-1 receptor agonists
provide pharmacologic levels of GLP-1 receptor stimulation,
whereasDPP-4iappeartoincreasecirculatinglevelsofGLP-1
to within the physiologic range [18].
GLP-1 receptors are additionally expressed in extra-
pancreatic tissue, having potential for the treatment of
obesity and for beneﬁcial cardio- and endothelioprotective
eﬀects. Because diabetic patients are prone to cardiovascular
disease, T2DM treatment strategies should address the
cardiovascular risk proﬁle, including blood pressure, lipids,Experimental Diabetes Research 3
and body weight proﬁle, in addition to intensive glycaemic
control.
Incretin-based therapies, both GLP-1 receptor agonists
and DPP-4i, unlike many other antidiabetic therapies (such
as sulphonylureas and insulin in particular), they do not
induce weight gain. Moreover therapy with GLP-1 receptor
agonists results in progressive and sustained signiﬁcant
weight loss in most patients [19, 20]. These agents exert
physiological eﬀect similar to those of native GLP-1, includ-
ing enhancement of glucose-dependent insulin secretion
and suppression of inappropriately high glucagon secretion.
Furthermore, they also slow gastric emptying and reduce
food intake. DPP-4i have similar actions to that of GLP-
1 receptor agonists; they also enhance glucose-dependent
insulin secretion and suppress glucagon, but they do not
delay gastric emptying or reduce food intake. In controlled
clinical trials the eﬀect of DPP4i on weight was neutral [21].
In a recent large retrospective study exenatide twice daily
wascomparedwithotherglucose-loweringagentsintermsof
their impact on cardiovascular events incidence. Despite the
higher prevalence of coronary artery disease (CAD), obesity,
hyperlipidemia, hypertension, and/or other comorbidities at
baseline, exenatide-treated patients were less likely to have
a CVD event than non-exenatide-treated ones (HR: 0.81,
95% CI: 0.68–0.95; P = .01). Furthermore, exenatide-
treated patients demonstrated lower rates of CVD-related
hospitalization (HR: 0.88, 95% CI: 0.79–0.98; P = .02) and
all-cause hospitalization (HR: 0.94, 95% CI: 0.91–0.97; P<
.001) than those not having received exenatide [22].
Emerging data suggest a cardioprotective eﬀect of DPP-
4i in humans. These drugs reduce HbA1c, although to
a lesser extent than sulphonylureas, with no weight gain
and low hypoglycaemic risk. The risk of cardiovascular
events and all-cause death, during DPP-4i treatment, is
0.76 [0.46–1.28] and 0.78 [0.40–1.51], respectively [23].
In particular, sitagliptin administration at a single dose of
100mg in patients with CAD and preserved left ventricular
(LV) function enhanced LV response to stress, attenuated
postischaemic stunning, and improved global and regional
LV performance compared to placebo [24]. Encouraging
resultshavealso been publishedfroma phase IIIrandomized
placebo-controlled trial regarding the granulocyte-colony
stimulating factor- (G-CSF) based stem cell mobilization
in combination with sitagliptin in patients after acute MI.
During the ﬁrst 6 weeks of followup, sitagliptin along
with G-CSF seems to be safe and eﬀective for myocardial
regeneration representing a new therapeutic option in the
future [25].
There are also data regarding the impact of GLP-1
receptor agonists and DPP-4i on endothelial function and
cardiovascular diseases biomarkers. In particular, an addi-
tional eﬀect of liraglutide on inﬂammatory process has been
reported, since it was related to a signiﬁcant reduction of
high-sensitivity C-reactive protein(hsCRP) circulating levels
in T2DM patients through a dose-dependent pathway [26].
Similar inhibitory eﬀectsonvascular cell adhesion molecule-
1 (VCAM-1) and hsCRP have been reported for exenatide
[27, 28]. Protective eﬀects on endothelial function have
beenalso described for sitagliptin, mainly through induction
Table 1
GLP-1 receptor agonists DPP-4 inhibitors
Administration Injection Oral
GLP-1 concentration Pharmacologic Physiologic
Insulin Secretion ++ +
Glucagon secretion −− −−
Action ↑ GLP-1 ↑ GLP-1 and GIP
Gastric emptying −±
Weight loss ++ =
β-cell protection ++∗ ++∗
Immunogenicity +◦ −
Nausea and vomiting + −
∗In animal model.
◦Not similar for diﬀerent GLP-1 receptor agonists according to their
homology to native peptide.
of NOS activity, and to greater extent in comparison to
pioglitazone [29].
Substantial evidence demonstrates that both GLP-1
receptor agonists and DPP-4i produce modest reductions in
systolic blood pressure and, in some cases, diastolic blood
pressure. The eﬀectoftheincretin hormoneson serum lipids
are either neutral or beneﬁcial, with small, nonsigniﬁcant
decreases in low-density lipoprotein cholesterol, increases in
high-density lipoprotein cholesterol, and occasionally signif-
icant decreases in fasting triglyceride levels. Furthermore,
GLP-1 receptor agonists showed positive eﬀects on hepatic
steatosis [30, 31].
T2DM is a progressive chronic disease characterized by
insulin resistance and impaired beta-cell function. Treat-
ments that prevent further beta-cell decline are therefore
essential for the management of type 2 diabetes. In vitro
and animal studies showed that GLP-1 promotes β-cell neo-
genesis and preservation and inhibits β-cell apoptosis [32].
Various human studies conﬁrmed GLP-1 receptor agonists
and DPP-4i eﬀects in β-cell function improvement [33–
35] but there is no evidence supporting β-cell proliferation
and/or antiapoptosis eﬀect in human yet.
Table 1 summarizes thediﬀerencesbetweenGLP-1recep-
tors agonists and DPP-4 inhibitors.
4.ClinicalUse ofGlucagon-Like
Peptide1 ReceptorAgonistsand
DipeptidylPeptidase4Inhibitors
4.1. GLP-1 Receptor Agonists. GLP-1 receptor agonists have,
to date, varying degrees of evidence to support their positive
eﬀectsonglycated hemoglobin(HbA1c)reductionin T2DM
patients.
Eﬃcacy and safety data for exenatide were derived from
three phase III Diabetes Management for Improving Glucose
Outcomes (AMIGO) trials in patients with T2DM who
were inadequately controlled with either a sulfonylurea,
metformin, or a sulfonylurea plus metformin [36–38].
In each of these trials, twice daily exenatide was shown
to reduce HbA1c signiﬁcantly, by approximately 0.9% from4 Experimental Diabetes Research
baseline over the 30-week trial period compared with place-
bo.Apooledanalysisoftrial dataplustwo52-weekextension
studies, which were completed by 314 of 1446 patients in
an intention-to-treat group from the 30-week randomized
trials, found that the reduction in HbA1c was sustained over
2y e a r s[ 39].
In T2DM patients not adequately controlled with met-
formin, exenatide showed noninferiority eﬀects on HbA1c
in comparison to basal insulin glargine add-on therapy, but
a better beta-cell function improvement and weight proﬁle
(diﬀerence −4.6kg, P<. 0001) [40].
In two open-label trials, exenatide was compared with
insulin treatment in patients inadequately controlled by
metforminplussulphonylurea.Intheﬁrststudy,551patients
were randomized to receive glargine once daily or exenatide
twicedaily.After26weeks, HbA1cfellby1.1%pointsinboth
groups (baseline: 8.2%). Exenatide reduced postprandial
glucose excursions more than insulin glargine, while insulin
glargine had a more pronounced eﬀect on fasting plasma
glucose. Body weight increased, as expected, by 1.8kg
with glargine while a 2.3kg weight loss was obtained with
exenatide. Nocturnal hypoglycaemia was less frequent with
exenatide [41]. Barnett et al. conﬁrmed these diﬀerences
in T2DM not adequately controlled with metformin or
sulphonylurea [42]. In the second 52-week trial, exenatide
was compared with twice daily biphasic insulin aspart.
Exenatide treatment resulted in HbA1c reduction similar
to biphasic insulin aspart and provided better postprandial
glycaemiccontrolandweightproﬁle(−2.5kgversus+2.9kg)
[43].
A recent meta-analysis of placebo-controlled clinical tri-
als assessing eﬃcacy of incretin-based medications in T2DM
patients showed that liraglutide both at 1.2 and 1.8mg is
associated with greater reductions in HbA1c in comparison
to exenatide (weighted mean diﬀerences, WMD = −0.75,
95% CI = −0.83 to −0.67, P<. 001), vildagliptin (WMD
= −0.67, 95% CI = −0.83 to −0.52, P<. 001), or sitagliptin
(WMD= −0.79,95%CI = −0.93to −0.65,P<. 001)[44].In
T2DM not adequately controlled with metformin, exenatide
and sulphonylurea are associated to similar improvement in
HbA1c levels, fasting and post prandial glycemia. However
exenatide add-on therapy induced weight loss, improve-
ment of insulin resistance indexes, and high-sensitivity C-
reactive protein (Hs-CRP) reduction versus glibenclamide
[45].
Liraglutide’s eﬃcacy and safety in combination with
otherhypoglycemictreatmenthasbeenextensivelyinvestiga-
ted in the phase III Liraglutide Eﬀect and Action in
Diabetes (LEAD) clinical development programme. Trials
duration ranged from 26 to 52 weeks, and several trials
have ongoing extension phases. In T2DM patients not
adequately controlled with sulphonylurea, liraglutide add-
on therapy resulted, in comparison to rosiglitazone, in
signiﬁcantly greater HbA1c reduction (treatment diﬀerences
forliraglutide1.8mg −0.7%(95%CI1.6;1.1)incomparison
to rosiglitazone, and −0.6% (95% CI 1.5; 1.1) for liraglutide
1.2mg), and in a signiﬁcantly better weight proﬁle [46].
Liraglutide in addition to metformin showed a noninferior
glycemic amelioration in comparison to sulphonylurea,
associated to a relatively low rate of reported minor hypo-
glycemia (0.03–0.14events/year) signiﬁcantly less than for
the glimepiride group (1.23events/year; P = .001) [47]. In
T2DM patients not adequately controlled with metformin
and sulphonylurea, liraglutide addition was signiﬁcantly
associated to greater reduction in HbA1c in comparison
to insulin glargine (treatment diﬀerences for liraglutide
versus insulin glargine −0.24%, 95% CI −0.39, −0.08; P =
.0015), positive weight eﬀects (mean treatment diﬀerence
of −3.43kg (95% CI −4.00, −2.86; P<. 0001) and waist
circumference reductions (treatment diﬀerence −2.40cm,
95% CI −3.14, −1.65; P<. 0001) [48].
LEAD-6 study (26 week) conﬁrmed, during liraglutide
(1.8mg) add-on therapy, a signiﬁcantly greater reduction of
HbA1c and fasting glycemia, less eﬀective postprandial glu-
cose control, and similar weight eﬀects (liraglutide −3.24kg
versus exenatide −2.87kg) in comparison to exenatide
(10μg) [49].
Currently, concomitant use of GLP-1 receptor agonist
andinsulin isnot recommendedbythemanufacturer. Poten-
tial concerns with combination therapy include additive
hypoglycemia, reduced patient adherence to another subcu-
taneously administered medication, and an estimated $200–
300additionalmonthlycostforthepatient.Inaretrospective
analysis evaluating the eﬀectiveness of exenatide and insulin
combination (N = 76) for 1 year, statistically signiﬁcant
reductions in HbA1c (mean 0.87% reduction) and weight
change (mean 5.2kg reduction) were observed. As reported
in the other clinical trials, there were signiﬁcant reductions
especially in bolus insulin dose, with 45% of patients
discontinuing short-acting insulin and a 35% reduction in
the mean daily dose of short-acting insulin [50]. These
compounds were safe; in fact the most common side eﬀects
are nausea, vomiting and diarrhea reported especially at the
beginning of the therapy; side eﬀects as pancreatitis and QT
prolongation during exenatide treatment are rare [18].
4.2. Dpp-4 Inhibitors. DPP-4i, also called incretin enhancers,
may be used as monotherapy or in combination with other
antidiabetic compounds. Sitagliptin, vildagliptin, and sax-
agliptin are already available in many countries, either as
single agents or in ﬁxed-dose combined formulations with
metformin. Other DPP-4i, such as alogliptin and linagliptin,
are currently in late phase of development.
All together gliptins have a good oral bioavailability
which is not signiﬁcantly inﬂuenced byfood intake.Pharma-
cokinetic/dynamic characteristics, as suﬃciently prolonged
half-life and sustained DPP-4 enzyme inactivation, gener-
ally allow one single oral administration per day for the
management of T2DM; the only exception is vildagliptin for
which a twice daily administration is recommended because
of a shorter half-life. DPP-4i are in general not substrates
for cytochrome P450 (except saxagliptin that is metabolized
via CYP 3A4/A5) and do not act as inducers or inhibitors
of this system [51, 52]. Several metabolites have been
documented but most of them are inactive; however, the
main metabolite of saxagliptin also exerts a signiﬁcant DPP-
4 inhibition and is half as potent as the parent compound.
Renal excretion is the most important elimination pathway,Experimental Diabetes Research 5
except for linagliptin whose excretion in the liver appears to
be predominant. PK properties of gliptins, combined with
their good safety proﬁle, explain why no dose adjustment
is necessary in elderly patients or in patients with mild
to moderate hepatic impairment. As far as patients with
renal impairment are concerned, signiﬁcant increases in
drug exposure for sitagliptin and saxagliptin have been
reported so that appropriate reductions in daily dosages are
recommended according to estimated glomerular ﬁltration
rate. The PK characteristics of DPP-4i suggest that these
compounds are not exposed to a high risk of drug-drug
interactions [53]. However, the daily dose of saxagliptin
should be reduced when coadministered with potent CYP
3A4 inhibitors. The DPP-4i improve glycaemic control,
reducing both fasting and postprandial glucose levels to
lower HbA1c levels, without weight gain and with an appar-
ently good adverse event proﬁle. At present, there seems
to be little to distinguish between the diﬀerent inhibitors
in terms of their eﬃcacy as antidiabetic agents and their
safety. In particular, vildagliptin monotherapy resulted in
improved glycemic control in drug-na¨ ıve patients with type
2d i a b e t e s[ 54]. Although the hypothesis of noninferiority to
gliclazide was not borne out statistically, the reductions in
HbA1c were similar over a two-year period and vildagliptin
had signiﬁcant beneﬁts in terms of less weight gain and
less hypoglycemia. Vildagliptin improves islet function in
T2DMunderfastingconditions[55].ThissuggeststhatDPP-
4 inhibition has metabolic beneﬁts in addition to enhancing
meal-induced GLP-1 and GIP activity. The weight neutrality
of vildagliptin likely results in part from its intrinsically
low risk for hypoglycemia [56]. Recent studies point to
additional potential mechanisms. One study found that
drug-na¨ ıve patients randomized to vildagliptin exhibited
signiﬁcantly lower chylomicron lipid and apolipoprotein
levels than placebo patients, suggesting that vildagliptin may
inhibit intestinal fat extraction. A meta-analysis indicates
that vildagliptin was not associated with increased risk of
hepatic events or hepatic enzyme elevations indicative of
drug-induced liver injury, pancreatitis, infections, or skin-
related toxicity [57]. The safety of vildagliptin in renal
transplant patients has been recently assessed [58, 59].
Sitagliptin monotherapy improved glycemic control
compared to placebo and was generally well tolerated in
patients with type 2 diabetes. The glycemic response to
treatment with sitagliptin 100mg/day was similar between
100-mg once daily and 50-mg twice daily dose regimens
[60]. Recent trials have shown that the combinations oﬀer
additive eﬃcacy in reducing blood glucose when given as
initial antidiabetic therapy and as add-on therapy when
pioglitazone alone fails to maintain glycemic control. The
combination of sitagliptin and pioglitazone was well toler-
ated and would appear to be suited to a ﬁxed-dose single-
tablet combination for once daily administration [61].
Preclinical and clinical trial data with sitagliptin to date
do not indicate an increased risk of pancreatitis [62].
Saxagliptin, 5mg once daily, has been shown to be
eﬀective in patients with type 2 diabetes treated with diet
alone, metformin, sulfonylurea, or glitazone, with a favour-
able tolerance proﬁle. Reduction in HbA1c levels averaged
0.6−0.8%, without increasing the risk of hypoglycaemia or
promoting weight gain [63]. In clinical trials, saxagliptin as
monotherapy or in combination with metformin, a sulpho-
nylurea (glyburide), or thiazolidinedione (pioglitazone or
rosiglitazone) signiﬁcantly improved glycemic control with-
out increasing hypoglycaemic eventsand weight versus com-
parator [64–68]. Furthermore, recent clinical data supported
the eﬃcacy and favorable tolerability proﬁle of a reduced
daily dose of saxagliptin (2.5mg) in T2DM patients with
a signiﬁcant renal impairment [69]. In conclusion, DPP-
4i have emerged as alternatives to sulfonylureas, commonly
used as add-on to metformin in treatment of T2DM. They
showed similar eﬃcacy to sulfonylureas but with lower risk
of hypoglycemia and reduction orno change in body weight,
and if conﬁrmed in humans, theymay preserveislet function
thereby minimizing the risk for secondary failure. Their
limitation at present is the lack of long-term experience on
durability and safety [21].
5.FuturePerspective
Few head-to-head clinical trials comparing diﬀerent incre-
tin-based drugs as add-on treatment are performed. Scheen
et al. showed similar eﬃcacy on glycaemia and tolerability
between saxagliptin and sitagliptin added to metformin in
T2DM patients inadequately controlled [70]. Liraglutide
providedsigniﬁcant betterimprovementinglycemiccontrol,
especially in fasting condition, in comparison to exenatide
twice daily [49]. Exenatide once weekly was associated with
signiﬁcantgreaterHbA1creduction(−1.5%,95%CI −1.7to
−1.4 versus −0.9%, −1.1 to −0.7) and weight loss (−2.3kg,
95%CI−2.9to −1.7versus −1.5kg,95%CI −2.4to −0.7)in
comparison to sitagliptin as add-on treatment to metformin
[71].
The proﬁle of action of GLP-1 receptor agonists and
DPP-4 inhibitors suggests the possibility of an actual reduc-
tion in cardiovascular risk, which needs to be conﬁrmed
by large long-term clinical trials, and beta cell protection,
to date only proven in animal models [72]. The use of
incretins is suggested very early in the type 2 diabetic history,
but some studies suggest a potential use of them also in
obesepatientsand inprediabeticpatients[73,74].Moreover,
recently liraglutide eﬃcacywas evaluatedin themanagement
of obese patients. This treatment was well tolerated during
20 weeks and associated to a signiﬁcant higher weight loss in
comparison to placebo and orlistat [73].
At present, GLP-1 receptor agonists need to be adminis-
tered by subcutaneous injection once or twice daily. Several
once weekly GLP-1 receptor agonists are in phase 3 clinical
trial development as exenatide once weekly, taspoglutide,
albiglutide, LY2189265, and CJC-1134-PC. A greater reduc-
tion in HbA1c and fasting plasma glucose was found with
the once weekly GLP-1 receptoragonists compared with exe-
natide BID, while the eﬀect on postprandial hyperglycemia
was modest. The reduction in HbA1c was in most studies
greater compared to oral antidiabetic drugs and insulin
glargine. The reduction in weight did not diﬀer between
the short- and long-acting agonists. The gastrointestinal side6 Experimental Diabetes Research
eﬀects were less with the once weekly agonists compared
with exenatide BID,except fortaspoglutide.Antibodies seem
to be most frequent with exenatide once weekly, while
hypersensitivity has been described in few patients treated
with taspoglutide.The developmentoftaspoglutidehasbeen
stopped because of safety problems. Injection site reactions
diﬀer among the long-acting GLP-1 receptor agonists and
are observed more frequently than with exenatide BID and
liraglutide. The once weekly GLP-1 receptor agonists are
promising candidates for the treatment of type 2 diabetes
although their eﬃcacy may not be superior to once daily
analogue liraglutide [75].
Hyperglycemia plays a major role in the development
of the microvascular and macrovascular complications of
diabetes.Withtheexceptionofmetformin,traditionalagents
used for the treatment of type 2 diabetes are able to
improveglycemia,buttheiruseisoftenlimitedbytreatment-
associated side eﬀects, including hypoglycemia, weight gain,
and edema and they do not have any positive eﬀect on
beta-cell mass or function. The introduction of incretin
hormone-based therapies represents a novel therapeutic
strategy, because these drugs not only improve glycemia
with minimal risk of hypoglycemia but also have other
extraglycemic beneﬁcial eﬀects. In clinical studies, both
exenatide and liraglutide, such as sitagliptin, vildagliptin,
and saxagliptin, improve β cell function and glycemia with
minimal hypoglycemia. All these agents have trophic eﬀects
on beta-cell mass in animal studies. The use ofthese agentsis
also associated with reduced or neutral eﬀect onbody weight
and improvements in blood pressure, diabetic dyslipidemia,
hepatic steatosis markers, and myocardial function. These
eﬀects have the potential to reduce the burden of cardiovas-
cular disease, which is a major cause of mortality in patients
with diabetes.
References
[1] J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates
of the prevalence of diabetes for 2010 and 2030,” Diabetes
Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010.
[ 2 ]R .S t u r m ,“ S t e m m i n gt h eg l o b a lo b e s i t ye p i d e m i c :w h a tc a n
we learn from data about social and economic trends?” Public
Health, vol. 122, no. 8, pp. 739–746, 2008.
[ 3 ]K .K .R a y ,S .R .K .S e s h a s a i ,S .W i j e s u r i y ae ta l . ,“ E ﬀect of
intensive control of glucose on cardiovascular outcomes and
death in patients with diabetes mellitus: a meta-analysis of
randomised controlled trials,” Lancet, vol. 373, no. 9677, pp.
1765–1772, 2009.
[4] E. Mannucci, M. Monami, C. Lamanna et al., “Prevention
of cardiovascular disease through glycemic control in type
2 diabetes: a meta-analysis of randomized clinical trials,”
Nutrition, Metabolism and Cardiovascular Diseases,vol.19,no.
9, pp. 604–612, 2009.
[5] V.Preumont,M.P.Hermans,S.Brichard,andM.Buysschaert,
“Six-monthexenatideimprovesHOMAhyperbolicproduct in
type2diabeticpatientsmostlybyenhancingbeta-cell function
rather than insulin sensitivity,” Diabetes Metab,v o l .3 6 ,n o .4 ,
pp. 293–8, 2010.
[6] A. Karasik, P. Aschner, H. Katzeﬀ,M .J .D a v i e s ,a n dP .P .S t e i n ,
“Sitagliptin, a DPP-4 inhibitor for the treatment of patients
with type 2 diabetes: a review of recent clinical trials,” Current
Medical Research and Opinion, vol. 24, no. 2, pp. 489–496,
2008.
[7] B. Ahr´ e n ,G .P a c i n i ,A .T u r a ,J .E .F o l e y ,a n dA .S c h w e i z e r ,
“Improved meal-related insulin processing contributes to
the enhancement of B-cell function by the DPP-4 inhibitor
vildagliptin in patients with type 2 diabetes,” Hormone and
Metabolic Research, vol. 39, no. 11, pp. 826–829, 2007.
[8] E. Mannucci, A. Ognibene, F. Cremasco et al., “Glucagon-like
peptide (GLP)-1 and leptin concentrations in obese patients
with type 2 diabetes mellitus,” Diabetic Medicine, vol. 17, no.
10, pp. 713–719, 2000.
[ 9 ]M .A .N a u c k ,I .V a r d a r l i ,C .F .D e a c o n ,J .J .H o l s t ,a n dJ .J .
Meier,“Secretion ofglucagon-likepeptide-1 (GLP-1)intype 2
diabetes: what is up, what is down?” Diabetologia, vol. 54, no.
1, pp. 10–8.
[10] C. M. Rotella, L. Pala, and E. Mannucci, “Glucagon-like pep-
tide 1 (GLP-1) and metabolic diseases,” Journal of Endocrino-
logical Investigation, vol. 28, no. 8, pp. 746–758, 2005.
[11] E. Mannucci, A. Ognibene, F. Cremasco et al., “Eﬀect of
metformin on glucagon-like peptide 1 (GLP-1) and leptin
levels in obese nondiabetic subjects,” Diabetes Care, vol. 24,
no. 3, pp. 489–494, 2001.
[ 1 2 ]E .M a n n u c c i ,F .T e s i ,G .B a r d i n ie ta l . ,“ E ﬀects of metformin
on glucagon-like peptide-1 levels in obese patients with and
withouttype 2diabetes,”Diabetes,nutrition&metabolism,v ol.
17, no. 6, pp. 336–342, 2004.
[13] E. Mannucci, L. Pala, M. Monami et al., “Glucagon-like
peptide-1 response to meals and post-prandial hyperglycemia
in type 2 diabetic patients,” Journal of Endocrinological Investi-
gation, vol. 33, no. 3, pp. 147–150, 2010.
[14] L. Pala, S. Ciani, I. Dicembrini et al., “Relationship between
GLP-1 levels and dipeptidyl peptidase-4 activity in diﬀerent
glucose tolerance conditions,” Diabetic Medicine, vol. 27, no.
6, pp. 691–695, 2010.
[15] L.Pala,E.Mannucci,A.Pezzatinietal.,“Dipeptidyl peptidase-
IV expression and activity in human glomerular endothelial
cells,” Biochemical and Biophysical Research Communications,
vol. 310, no. 1, pp. 28–31, 2003.
[16] E. Mannucci, L. Pala, S. Ciani et al., “Hyperglycaemia
increases dipeptidyl peptidase IV activity in diabetes mellitus,”
Diabetologia, vol. 48, no. 6, pp. 1168–1172, 2005.
[ 1 7 ]L .P a l a ,A .P e z z a t i n i ,I .D i c e m b r i n ie ta l . ,“ D i ﬀerent modula-
tion of dipeptidyl peptidase-4 activity between microvascular
and macrovascular human endothelial cells,” Acta Diabetol.I n
press.
[18] M. A. Nauck, “Incretin-based therapies for type 2 diabetes
mellitus: properties, functions, and clinical implications,”
American Journal of Medicine,vol.124,no.1,pp. s3–s18,2011.
[19] A. Varanasi, A. Chaudhuri, S. Dhindsa et al., “Durability
of eﬀects of exenatide treatment on glycemic control, body
weight, systolic blood pressure, Crp and triglyceride concen-
trations,” Endocrine Practice, vol. 17, no. 2, pp. 192–200, 2010.
[20] M. J. Davies, R. Kela, and K. Khunti, “Overview of the
preclinical and clinical data and its role in the treatment of
type 2 diabetes,” Diabetes, Obesity and Metabolism,v ol.13,no .
3, pp. 207–20, 2011.
[21] B. Ahr´ en, “Are sulfonylureas less desirable than DPP-4
inhibitors as add-on to metformin in the treatment of type
2d i a b e t e s ?”Current diabetes reports . In press.
[ 2 2 ]J .H .B e s t ,B .J .H o o g w e r f ,W .H .H e r m a ne ta l . ,“ R i s ko f
cardiovascular disease events in patients with type 2 diabetes
prescribed the glucagon-like peptide 1 (GLP-1) receptor ago-
nist exenatide twice daily or other glucose-lowering therapies:Experimental Diabetes Research 7
aretrospective analysisofthelifeLinkdatabase,”DiabetesCare,
vol. 34, no. 1, pp. 90–5, 2011.
[23] M. Monami, I. Iacomelli, N. Marchionni, and E. Mannucci,
“Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-
analysis of randomized clinical trials,” Nutrition, Metabolism
and Cardiovascular Diseases,vol. 20, no. 4, pp. 224–235, 2010.
[24] P .A.R ead,F .Z.Khan,P .M.H eck,S.P .H oole,andD .P .Dutka,
“DPP-4 inhibition by sitagliptin improves the myocardial
response to dobutamine stress and mitigates stunning in
a pilot study of patients with coronary artery disease,”
Circulation: Cardiovascular Imaging, vol.3, no.2,pp. 195–201,
2010.
[25] H. D. Theiss, C. Brenner, M. G. Engelmann et al., “Safety and
eﬃcacy of SITAgliptin plus GRanulocyte-colony-stimulating
factor in patients suﬀering from acute myocardial infarction
(SITAGRAMI-Trial)–Rationale, design and ﬁrst interim anal-
ysis,” International Journal of Cardiology, 2010.
[26] J. P. Courr` eges, T. Vilsbøll, M. Zdravkovic et al., “Bene-
ﬁcial eﬀects of once-daily liraglutide, a human glucagon-
like peptide-1 analogue, on cardiovascular risk biomarkers in
patients with type 2 diabetes,” Diabetic Medicine,v o l .2 5 ,n o .
9, pp. 1129–1131, 2008.
[27] P. Viswanathan, A. Chaudhuri, R. Bhatia, F. Al-Atrash, P.
Mohanty, and P. Dandona, “Exenatide therapy in obese
patients with type 2 diabetes mellitus treated with insulin,”
Endocrine Practice, vol. 13, no. 5, pp. 444–450, 2007.
[28] M.Arakawa,T.Mita,K.Azumaetal.,“Inhibitionofmonocyte
adhesiontoendothelialcellsandattenuationofatherosclerotic
lesion by a glucagon-like peptide-1 receptor agonist, exendin-
4,” Diabetes, vol. 59, no. 4, pp. 1030–1037, 2010.
[ 2 9 ]Y .Y e ,K .T .K e y e s ,C .Z h a n g ,J .R .P e r e z - P o l o ,Y U .L i n ,a n d
Y. Birnbaum, “The myocardial infarct size-limiting eﬀect of
sitagliptin is PKA-dependent, whereas the protective eﬀect of
pioglitazoneis partially dependent on PKA,” American Journal
of Physiology, vol. 298, no. 5, pp. H1454–1465, 2010.
[30] D. C. Klonoﬀ,J .B .B u s e ,L .L .N i e l s e ne ta l . ,“ E x e n a t i d ee ﬀects
on diabetes, obesity, cardiovascular risk factors and hepatic
biomarkers in patients with type 2 diabetes treated for at least
3y e a r s , ”Current Medical Research and Opinion, vol. 24, no. 1,
pp. 275–286, 2008.
[ 3 1 ]J .J e n d l e ,M .A .N a u c k ,D .R .M a t t h e w se ta l . ,“ L E A D - 2a n d
LEAD-3 study groups. weight loss with liraglutide, a once-
daily human glucagon-like peptide-1 analogue for type 2
diabetes treatment as monotherapy or added to metformin,
is primarily as a result of a reduction in fat tissue,” Diabetes,
Obesity and Metabolism, vol. 11, no. 12, pp. 1163–72, 2009.
[32] S. R. Drab, “Incretin-based therapies for type 2 diabetes mel-
litus: current status and future prospects,” Pharmacotherapy,
vol. 30, no. 6, pp. 609–624, 2010.
[33] L. Blonde and D. Russell-Jones, “The safety and eﬃcacy of
liraglutide with or without oral antidiabetic drug therapy
in type 2 diabetes: an overview of the LEAD 1-5 studies,”
Diabetes, Obesity and Metabolism, vol. 11, no. 3, pp. 26–34,
2009.
[34] W. Wang, J. R. Walker, X. Wang et al., “Identiﬁcation of small-
molecule inducers of pancreatic β-cell expansion,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 106, no. 5, pp. 1427–1432, 2009.
[35] B. L. Wajchenberg, “Beta-cell failure in diabetes and preserva-
tion by clinical treatment,” Endocrine Reviews,v o l .2 8 ,n o .2 ,
pp. 187–218, 2007.
[36] D. M. Kendall, M. C. Riddle, J. Rosenstock et al., “Eﬀects
of exenatide (exendin-4) on glycemic control over 30 weeks
in patients with type 2 diabetes treated with metformin and
as u l f o n y l u r e a , ”Diabetes Care, vol. 28, no. 5, pp. 1083–1091,
2005.
[ 3 7 ]J .B .B u s e ,R .R .H e n r y ,J .H a n ,D .D .K i m ,M .S .F i n e m a n ,
and A. D. Baron, “For the e xenatide-113 clinical study group.
eﬀects of exenatide (exendin-4) on glycemic control over 30
weeks in sulfonylurea-treated patients with type 2 diabetes,”
Diabetes Care, vol. 27, pp. 2628–3, 2004.
[ 3 8 ]R .A .D e F r o n z o ,R .E .R a t n e r ,J .H a n ,D .D .K i m ,M .S .
F i n e m a n ,a n dA .D .B a r o n ,“ E ﬀects of exenatide (exendin-4)
on glycemic control and weight over 30 weeks in metformin-
treated patients with type 2,” Diabetes Care, vol. 28, no. 5, pp.
1092–1100, 2005.
[39] L. Blonde, E. J. Klein, J. Han et al., “Interim analysis of the
eﬀects of exenatide treatment on A1C, weight and cardiovas-
cularriskfactorsover82weeksin314overweightpatientswith
type 2 diabetes,” Diabetes, Obesity and Metabolism,v o l .8 ,n o .
4, pp. 436–447, 2006.
[40] M. C. Bunck, M. Diamant, A. Corn´ er et al., “One-year treat-
ment with exenatide improves beta-cell function, compared
with insulin glargine, in metformin-treated type 2 diabetic
patients: a randomized, controlled trial,” Diabetes Care,v o l .
32, no. 5, pp. 762–8, 2009.
[ 4 1 ] R .J .H e i n e ,L .F .V a nG a a l ,D .J o h n s ,M .J .M i h m ,M .H .W i d e l ,
a n dR .G .B r o d o w s ,“ G W A As t u d yg r o u p .e x e n a t i d ev e r s u s
insulin glargine in patients with suboptimally controlled type
2 diabetes: a randomized trial,” Annals of Internal Medicine,
vol. 143, no. 8, pp. 559–69, 2005.
[42] A. H. Barnett, J. Burger, D. Johns et al., “Tolerability and
eﬃcacy of exenatide and titrated insulin glargine in adult
patients with type 2 diabetes previously uncontrolled with
metformin or a sulfonylurea: a multinational, randomized,
open-label, two-period, crossover noninferiority trial,” Clin-
ical Therapeutics, vol. 29, no. 11, pp. 2333–2348, 2007.
[43] M. A. Nauck, S. Duran, D. Kim et al., “A comparison of
twice-daily exenatide and biphasic insulin aspart in patients
with type 2 diabetes who were suboptimally controlled
with sulfonylurea and metformin: a non-inferiority study,”
Diabetologia, vol. 50, no. 2, pp. 259–267, 2007.
[44] W. K. Fakhoury, C. LeReun, and D. Wright, “A meta-analysis
of placebo-controlled clinical trials assessing the eﬃcacy and
safety of incretin-based medications in patients with type 2
diabetes,” Pharmacology, vol. 86, no. 1, pp. 44–57, 2010.
[45] G. Derosa, P. Maﬃoli, S. A. Salvadeo et al., “Exenatide versus
glibenclamide in patients with diabetes,” Diabetes Technology
&T h e r a p e u t i c s, vol. 12, no. 3, pp. 233–40, 2010.
[46] M.Marre,J.Shaw,M.Br¨ andleet al.,“LEAD-1 SUstudy group.
liraglutide, a once-daily human GLP-1 analogue, added to a
sulphonylurea over 26 weeks produces greater improvements
in glycaemic and weight control compared with adding
rosiglitazone or placebo in subjects with type 2 diabetes
(LEAD-1 SU),” Diabetic Medicine, vol. 26, no. 3, pp. 268–78,
2009.
[47] M.Nauck,A.Frid, K.Hermansenet al.,“LEAD-2 studygroup.
eﬃcacy and safety comparison of liraglutide, glimepiride,
and placebo, all in combination with metformin, in type 2
diabetes: the LEAD(liraglutideeﬀect andactionin diabetes)-2
study,” Diabetes Care, vol. 32, no. 1, pp. 84–90, 2009.
[48] D. Russell-Jones, A. Vaag, and O. Schmitz, “Liraglutide vs
insulin glargine and placebo in combination with metformin
and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-
5 met+SU): a randomized controlled trial liraglutide eﬀect
and action in diabetes 5 (LEAD-5) met+SU study group,”
Diabetologia, vol. 52, no. 10, pp. 2046–55, 2009.8 Experimental Diabetes Research
[49] J. B. Buse, J. Rosenstock, G. Sesti et al., “LEAD-6 study
g r o u p . l i r a g l u t i d eo n c ead a yv e r s u se x e n a t i d et w i c ead a y
for type 2 diabetes: a 26-week randomised, parallel-group,
multinational, open-label trial (LEAD-6),” Lancet, vol. 374,
no. 9683, pp. 39–47, 2009.
[50] C. A. Sheﬃeld, M. P. Kane, R. S. Busch et al., “Safety and
eﬃcacy of exenatide in combination with insulin in patients
with type 2 diabetes mellitus,” Endocrine Practice, vol. 14, no.
3, pp. 285–292, 2008.
[51] A. J. Scheen, “Pharmacokinetics of dipeptidylpeptidase-4 in-
hibitors,”Diabetes, Obesity and Metabolism:,v ol.12,no .8,p p .
648–58, 2010.
[52] A. J. Scheen, “Dipeptidylpeptidase-4 inhibitors (gliptins):
focusondrug-drug interactions,”Clin Pharmacokinet,v ol.49,
no. 9, pp. 573–88, 2010.
[53] C. F. Deacon, “Dipeptidyl peptidase-4 inhibitors in the
treatment of type 2 diabetes: a comparative review,” Diabetes,
Obesity and Metabolism, vol. 13, no. 1, pp. 7–18, 2011.
[54] J. E. Foley and S. Sreenan, “Eﬃcacy and safety comparison
between the DPP-4 inhibitor vildagliptin and the sulfonylurea
gliclazide after two years of monotherapy in drug-na¨ ıve
patients with type 2 diabetes,” Horm Metab Res, vol. 41, no.
12, pp. 905–9, 2009.
[55] D. A. D’Alessio, A. M. Denney, L. M. Hermiller et al., “Treat-
ment with the dipeptidyl peptidase-4 inhibitor vildagliptin
improves fasting islet-cell function in subjects with type 2
diabetes,” Journal of Clinical Endocrinology and Metabolism,
vol. 94, no. 1, pp. 81–88, 2009.
[56] J. E. Foley and J. Jordan, “Weight neutrality with the DPP-4
inhibitor, vildagliptin: mechanistic basis and clinical experi-
ence,” Vascular Healthand Risk Management,vol.6,pp. 541–8,
2010.
[57] M.Ligueros-Saylan,J.E.Foley,A.Schweizer,A.Couturier, and
W. Kothny, “An assessment of adverse eﬀects of vildagliptin
versus comparators on the liver, the pancreas, the immune
system, the skin and in patients with impaired renal function
from a large pooled database ofphase II and III clinicaltrials,”
Diabetes, Obesity and Metabolism, vol. 12, no. 6, pp. 495–509,
2010.
[58] M. Haidinger, J. Werzowa, H. C. Voigt et al., “A randomized,
placebo-controlled, double-blind, prospective trial to evaluate
the eﬀect of vildagliptin in new-onset diabetes mellitus after
kidney transplantation,” Trials, vol. 11, no. 1, p. 91, 2010.
[59] M. A. Banerji, D. Purkayastha, and B. H. Francis, “Safety and
tolerability of vildagliptin vs. thiazolidinedione as add-on to
metformin in type 2 diabetic patients with and without mild
renal impairment: a retrospective analysis of the GALIANT
study,” Diabetes Research and Clinical Practice ,v o l .9 0 ,n o .2 ,
pp. 182–90, 2010.
[ 6 0 ]M .H a n e f e l d ,G .A .H e r m a n ,M .W u ,C .M i c k e l ,M .S a n c h e z ,
and P. P. Stein, “Sitagliptin study 014 investigators.once-
daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the
treatment of patients with type 2 diabetes,” Current Medical
Research and Opinion, vol. 23, no. 6, pp. 1329–39, 2007.
[61] C. J. Bailey, B. D. Green, and P. R. Flatt, “Fixed-dose
combination therapy for type 2 diabetes: sitagliptin plus
pioglitazone,”Expert OpiniononInvestigationalDrugs,vol.19,
no. 8, pp. 1017–25, 2010.
[62] S. S. Engel, D. E. Williams-Herman, G. T. Golm et al.,
“Sitagliptin: review of preclinical and clinical data regarding
incidence of pancreatitis,” International Journal of Clinical
Practice, vol. 64, no. 7, pp. 984–990, 2010.
[63] A. J. Scheen, “Saxagliptin (Onglyza): new inhibitor of the
dipeptidylpeptidase-4 for the oral treatment of type 2 dia-
betes,” R e v u eM e d i c a l eD eL i e g e , vol. 65, no. 9, pp. 527–32,
2010.
[64] J. Rosenstock, C. Aguilar-Salinas, E. Klein et al., “Eﬀect of
saxagliptin monotherapy in treatment-na¨ ıve patients with
type 2 diabetes,” Current Medical Research and Opinion,v o l .
25, no. 10, pp. 2401–2411, 2009.
[65] M. Jadzinsky, A. Pf¨ utzner, E. Paz-Pacheco et al., “Saxagliptin
given in combination with metformin as initial therapy
improves glycaemic control in patients with type 2 diabetes
compared with either monotherapy: a randomized controlled
trial,”Diabetes,ObesityandMetabolism,vol.11,no.6,pp.611–
622, 2009.
[66] A. R. Chacra, G. H. Tan, A. Apanovitch, S. Ravichandran, J.
List, and R. Chen, “Saxagliptin added to a submaximal dose
of sulphonylurea improves glycaemic control compared with
uptitration of sulphonylurea in patients with type 2 diabetes:
arandomisedcontrolledtrial,”International JournalofClinical
Practice, vol. 63, no. 9, pp. 1395–1406, 2009.
[67] P. Hollander, J. Li, E. Allen, and R. Chen, “For the CV181-
013 investigators.saxagliptin added to a thiazolidinedione
improves glycemic control in patients with type 2 diabetes
and inadequate control on thiazolidinedione alone,” Journal
of Clinical Endocrinology and Metabolism, vol. 94, no. 12, pp.
4810–4819, 2009.
[ 6 8 ]R .A .D e F r o n z o ,M .H i s s a ,A .J .G a r b e re ta l . ,“ T h ee ﬃcacy
and safety of saxagliptin when added to metformin therapy
in patients with inadequately controlled type 2 diabetes with
metforminalone,”DiabetesCare,vol.32,no.9,pp.1649–1655,
2009.
[69] M. Nowicki, I. Rychlik, H. Haller, M. L. Warren, L. Suchower,
andI.Gause-Nilsson,“Saxagliptinimprovesglycaemiccontrol
and is well tolerated in patients with type 2 diabetes mellitus
and renal impairment,” Diabetes, Obesity and Metabolism,v o l .
13, no. 6, pp. 523–532, 2011.
[70] A. J. Scheen, G. Charpentier, C. J. Ostgren, A. Hellqvist,
and I. Gause-Nilsson, “Eﬃcacy and safety of saxagliptin in
combination with metformin compared with sitagliptin in
combination with metformin in adult patients with type 2
diabetes mellitus,” Diabetes Metab Res Rev,v o l .2 6 ,n o .7 ,p p .
504–9, 2010.
[ 7 1 ] R .M .B e r g e n s t a l ,C .W y s h a m ,L .M a c c o n e l le ta l . ,
“DURATION-2 study group. eﬃcacy and safety of exenatide
once weekly versus sitagliptin or pioglitazone as an adjunct to
metformin for treatment of type 2 diabetes (DURATION-2):
a randomised trial,” Lancet, vol. 376, no. 9739, pp. 431–439,
2010.
[ 7 2 ]E .M a n n u c c ia n dC .M .R o t e l l a ,“ F u t u r ep e r s p e c t i v e so n
glucagon-like peptide-1, diabetes and cardiovascular risk,”
Nutrition, Metabolismand Cardiovascular Diseases,vol.18,no.
9, pp. 639–645, 2008.
[73] A Astrup, S R¨ ossner, L Van Gaal et al., “NN8022-1807 study
group. eﬀects of liraglutide in the treatment of obesity: a
randomised, double-blind, placebo-controlled study.,” Lancet,
vol. 374, no. 9701, pp. 1606–16, 2009.
[74] G. Bock, C. Dalla Man, F. Micheletto et al., “The eﬀect of
DPP-4 inhibition with sitagliptin on incretin secretion and
on fasting and postprandial glucose turnover in subjects with
impaired fasting glucose,” Clinical Endocrinology (Oxf),v o l .
73, no. 2, pp. 189–196, 2010.
[ 7 5 ]S .M a d s b a d ,U .K i e l g a s t ,M .A s m a r ,C .D e a c o n ,S .S .T o r e k o v ,
and J. J. Holst, “An overview of once-weekly GLP-1 receptor
agonists-availableeﬃcacyandsafetydata andperspectives for
the future,” Diabetes, Obesity and Metabolism, vol. 13, no. 5,
pp. 394–407, 2011.